Navigation Links
Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Date:11/14/2011

TORONTO, Nov. 14, 2011 /PRNewswire/ -- Modern Mobility Aids, Inc. (MDRM.OB) (the "Company"), headquartered in Nevada, USA, has completed its due diligence on the acquisition of all the common stock of Lumigene Technologies, Inc. ("Lumigene") and expects to close on the transaction by November 30, 2011.

LumiGene is a Canadian molecular diagnostics company developing point-of-care healthcare products for quick and effective pathogen and disease detection.  The acquisition of Lumigene will allow the Company to address the increasing demand from healthcare professionals worldwide for more rapid and cost-efficient DNA testing, especially for point-of-care products enabling immediate diagnosis.  Current testing methods take days to perform by specially-trained technical personnel in an offsite laboratory environment. There is a large need to speed up the DNA sample preparation, amplification and detection at the sample collection site to obtain immediate and accurate results.

Mohamed K. Karatella, President and CEO, elaborated on the portable and easy-to-use products being developed for commercialization by Lumigene: "Staff at hospitals, health clinics and even airports need fast detection of pathogens, infectious diseases and other ailments right at the point of DNA sampling.  Delivering the first available solution to produce such reliable results within an hour with Lumigene's automated and economic technology will open up a broad range of applications and global market potential.  We are very pleased to welcome the talented technical team at Lumigene to add to our management strength and bring further innovative bioscience technologies to our Company."

A significant portion of the purchase price for Lumigene will be paid based on the achievement of key business and technology milestones, including patent application filing, development of a "Beta Cartridge" and successful completion of external Beta testing of Lumigene's POSiChek™ System within the deadlines agreed to by the Company.  This acquisition of Lumigene will help the Company expedite its healthcare innovation strategy.

About Modern Mobility Aids, Inc.

Modern Mobility Aids, Inc. was first incorporated under the laws of the State of Nevada on December 19, 2007, under the name of Glider Inc. Its business plan was to sell and distribute products for mobility-challenged individuals. The Company changed its name to Modern Mobility Aids, Inc. on April 22, 2010 with initial plans to distribute products for mobility-challenged individuals. In May of 2011, the business focus of the Company evolved with a rapid expansion strategy in the life sciences and healthcare industry.  A mandate was created to acquire companies within the biopharma sector, targeting both innovative research and development as well as scalable manufacturing capacity in three niche market segments: CRAM (Contract Research and Manufacturing for Life Sciences Companies), HEALTHCARE INNOVATION (Novel Drug and Device Delivery Format Packaging) and BIOPHARMA PARTNERSHIPS (Strategic Development and Production Alliances).

CONTACT INFO:
Modern Mobility Aids, Inc.
Public Relations and Shareholder Information:
416 901 8831 investor@mdrmgroup.com


'/>"/>
SOURCE Modern Mobility Aids, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Modern Plastics Announces ISO 13485:2003 Certification for Medical Industry
2. Modern Plastics Announces Full Operation of Its New Facility in Shelton, Conn.
3. LasikPlus® Research Reveals Excellent Results From Modern LASIK
4. Modern Plastics SUSTARIN® C (Acetal) Product Uses Special Manufacturing Technology to Ensure Every Sheet and Rod Are Free of Centerline or Core Porosity
5. Advance could change modern electronics
6. Global Food Security Depends on Modern Agriculture
7. DuPont Leader: Drought-Tolerant Crops Developed Through Modern Breeding are Key to Sustainably Increasing Grain Production
8. New research reveals the ancestral populations of India and their relationships to modern groups
9. MIT: Alarming use of energy in modern manufacturing methods
10. DNA 11 Unveils Modern-Day Family Portraits at The Museum of Science and Industry's Smart Home: Green + WIRED Exhibit
11. The Modern DeBakey VAD™ To Be Introduced For the First Time in the U.S. : HeartAssist 5™ Pediatric VAD Features Industry Exclusive Direct Blood Flow Measurement System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 27, 2017 A Europe-wide survey of institutes ... using animals in their research treat them with due care. The ... detailed analysis of the results indicates that there is a strong ... put into practice the principles of the 3Rs (Refine, Reduce, ... What are ...
(Date:2/27/2017)... REDWOOD CITY, Calif. , Feb. 27, 2017 ... specialty pharmaceutical company focused on the development and ... moderate-to-severe acute pain, announced today the U.S. Food ... New Drug Application (NDA) under section 505(b)(2) for ... for the treatment of patients with moderate-to-severe acute ...
(Date:2/27/2017)... HAMILTON, Bermuda , Feb. 27, 2017 /PRNewswire/ ... ) and SELLAS Life Sciences Group , ... immunotherapies, today announced that Advaxis has granted SELLAS ... agent using Advaxis, proprietary Lm -based antigen ... peptide antigen mixture (galinpepimut-S). Advaxis, ...
(Date:2/27/2017)... URBANDALE, Iowa (PRWEB) , ... February 27, 2017 , ... ... is following the advice of his grandfather, “Hire for attitude. Train for skill.” , ... State University star linebacker Jevohn Miller as a salesman. Zamzow is hoping to replicate ...
Breaking Biology Technology:
(Date:2/24/2017)... BARCELONA, Spain , Feb. 24, 2017  EyeLock LLC, ... will demonstrate its elite iris biometric solution on ... with X16 LTE at Mobile World Congress ... in Qualcomm,s Booth in Hall 3, Stand ... contains the Qualcomm Haven™ security platform—a combination ...
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):